^
    4ms
    A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Takeda | Trial completion date: Dec 2026 --> Jul 2026 | Trial primary completion date: Dec 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    NIB102
    11ms
    A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=18 --> 11
    Enrollment closed • Enrollment change
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    NIB102
    over1year
    Interim results of FIH Phase 1 of TAK-102, GPC-3 targeted armored CAR-T therapy in patients with advanced solid tumors (JSMO 2023)
    No abstract available
    Clinical • P1 data • Metastases
    |
    GPC3 (Glypican 3)
    |
    NIB102
    over1year
    A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Takeda | Trial completion date: Jul 2023 --> Dec 2026 | Trial primary completion date: Jul 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    NIB102
    2years
    Interim results of a first-in-human Phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors (SITC 2022)
    TAK-102 is administered via a single infusion on 3 dose cohorts after lymphodepleting chemotherapy (fludarabine and cyclophosphamide): Cohort 1 (starting cohort), 1x10 7 CAR+ cells/body; Cohort 2, 1x10 8 CAR+ cells/body; Cohort 3, 1x10 9 CAR+ cells/body. Preliminary data show an encouraging safety profile and CK/PD results. The dose-escalation study is ongoing ( NCT04405778 ).
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
    |
    IFNG (Interferon, gamma) • AFP (Alpha-fetoprotein) • CD69 (CD69 Molecule) • GPC3 (Glypican 3) • IL10 (Interleukin 10) • CCL19 (C-C Motif Chemokine Ligand 19) • GZMB (Granzyme B) • IL7 (Interleukin 7) • GPI (Glucose-6-Phosphate Isomerase)
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • fludarabine IV • NIB102
    3years
    A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Takeda | Trial completion date: Nov 2022 --> Jul 2023 | Trial primary completion date: Nov 2022 --> Jul 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    NIB102
    over4years
    A Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors (clinicaltrials.gov)
    P1; N=18; Recruiting; Sponsor: Takeda; Not yet recruiting --> Recruiting
    Enrollment open • Clinical
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    NIB102